Daehan Nupharm대한뉴팜
054670 · KOSDAQ · ₩054670 · 대한뉴팜
₩5,100▼ ₩10 (0.20%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 42.6% | 45.6% | 47.9% | 46.0% | 45.7% | 50.4% |
| Operating margin | 4.6% | 5.8% | 9.2% | 9.2% | 13.9% | 16.0% |
| Net margin | 11.1% | 7.5% | 7.7% | 6.1% | 12.3% | 9.4% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +4.5% | +0.1% | −1.0% | +3.2% | +18.8% | — |
| Operating income growth | −17.2% | −37.2% | −0.8% | −31.8% | +3.3% | — |
| Net income growth | +54.1% | −1.4% | +23.3% | −48.4% | +54.9% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 16.3% | 11.5% | 13.2% | 11.8% | 26.2% | 19.0% |
| Return on assets | 8.5% | 6.2% | 7.8% | 7.2% | 14.9% | 10.0% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 88.8% | 93.8% | 76.4% | 61.8% | 64.5% | 91.2% |
| Net debt to equity | 42.0% | 46.4% | 22.3% | 13.4% | 14.4% | 25.3% |
| Current ratio | 176.2% | 155.2% | 160.5% | 159.5% | 175.2% | 168.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Daehan Nupharm / 대한뉴팜 / 054670 / KRX:054670
Source: KRX statistical information